- Record: found
- Abstract: not found
- Article: not found
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck ,
Delvys Rodríguez-Abreu ,
Andrew G. Robinson ,
Rina Hui ,
Tibor Csőszi ,
Andrea Fülöp ,
Maya Gottfried ,
Nir Peled ,
Ali Tafreshi ,
Sinead Cuffe ,
Mary O’Brien ,
Suman Rao ,
Katsuyuki Hotta ,
Melanie A. Leiby ,
Gregory M. Lubiniecki ,
Yue Shentu ,
Reshma Rangwala ,
Julie R. Brahmer
November 10 2016
November 10 2016
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d15059184e193">Pembrolizumab is a humanized monoclonal antibody
against programmed death 1 (PD-1)
that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased
activity in tumors that express programmed death ligand 1 (PD-L1).
</p>